@article{fda298601d5d4c48b41dcfe13558ccef,
title = "Mavacamten for hypertrophic obstructive cardiomyopathy – Authors' reply",
author = "Daniel Jacoby and Ho, {Carolyn Y.} and Lester, {Steven J.} and Andrew Wang and Iacopo Olivotto",
note = "Funding Information: DJ has received personal fees from MyoKardia. CYH has received payments as a consultant from MyoKardia and Ambry Genetics. SJL has received payments as a consultant from MyoKardia. AW has received grants from MyoKardia; personal fees from Cytokinetics; and payments as a consultant from MyoKardia. IO has received grants from MyoKardia, Sanofi-Genzyme, Shire, and Bayer; personal fees from Sanofi-Genzyme, Shire, and Bayer; and payments as a consultant from MyoKardia.",
year = "2021",
month = jan,
day = "30",
doi = "10.1016/S0140-6736(20)32391-6",
language = "English (US)",
volume = "397",
pages = "369--370",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10272",
}